NASDAQ$DH
Definitive Healthcare Corp · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results with revenue exceeding guidance and adjusted EBITDA at the top end of the range.
Definitive Healthcare reported a strong Q3 2022 with revenue increasing by 33% year-over-year to $57.4 million. The company's adjusted EBITDA was $16.4 million, representing 29% of revenue, and they experienced key customer wins and product innovations.
- Revenue was $57.4 million, a 33% increase from Q3 2021.
- Net loss was ($6.4) million, or 11% of revenue.
- Adjusted Net Income was $8.9 million, compared to $2.2 million in Q3 2021.
- Adjusted EBITDA was $16.4 million, or 29% of revenue.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$57.4M
Forward guidance
The Company is issuing financial guidance for Q4 2022 and full year 2022.
Tailwinds
- Revenue is expected to be in the range of $58–59 million, a median 26% increase year over year.
- Adjusted Operating Income is expected to be in the range of $15 – 16 million.
- Adjusted EBITDA is expected to be in the range of $16–17 million.
- Adjusted Net Income is expected to be $6–7 million.
- Adjusted Net Income Per Diluted Share is expected to be $0.03–0.04 on approximately 156.5 million weighted-average shares outstanding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro